Key clinical point: The HSD3B1(1245C) allele is a risk factor for castration-resistant prostate cancer and poor outcomes in men with low-volume, advanced prostate cancer.
Major finding: The hazard ratios for castration-resistant prostate cancer and death among patients with the adrenal-permissive HSD3B1(1245C) allele were 1.89 and 1.74, respectively, compared with those with the adrenal-restrictive genotype.
Study details: Retrospective analysis of 475 white men enrolled in the CHAARTED trial.
Disclosures: The trial was funded by the National Cancer Institute. The authors disclosed relationships with several pharmaceutical companies. One author is a coinventor on a patent for a treatment method based on HSD3B1.
Hearn JWD et al. JAMA Oncol. 2020. doi: 10.1001/jamaoncol.2019.6496.